[1] |
NIE Yang, WANG Yue, WEI Jia.
Research progress on targeted therapy combined with immune-activating strategies in CLDN18.2-positive gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 146-158.
|
[2] |
CHEN Zhiwen, WANG Longrong, WANG Lu.
Current status and progress of targeted therapy for hepatocellular carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 171-182.
|
[3] |
DU Nan, WEI Miaoyan, XU Jin.
Advancements and frontiers in targeted therapy for pancreatic cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 183-192.
|
[4] |
JIANG Haitao, XU Yangxian .
Research progress on the resistance mechanism of anti-angiogenesis targeted drugs in the treatment of colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 193-199.
|
[5] |
LAN Xueling, HUANG Yanni, ZHU Minmin, MA Ping, DONG Min.
Advances of VEGF signalling pathway in hepatocellular carcinomar invasion and metastasis and therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 707-714.
|
[6] |
BAI Haodong, SHA Bingxian, Ambedkar Kumar Yadav, XU Xianghuai, YU Li .
Targeted biotherapy for chronic obstructive pulmonary disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 377-382.
|
[7] |
WANG Linlin, MA Yuan, CHEN Zhihong, JI Haiying .
Progress in the application of AIT in allergic airway diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 427-431.
|
[8] |
ZHANG Zhipeng, CHEN Ziqi, TIAN Jianhui.
The attenuating and potentiating effects of traditional Chinese medicine in immune checkpoint therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(3): 339-347.
|
[9] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[10] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[11] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[12] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[13] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[14] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|
[15] |
CHEN Manxin, ZHANG Bingyu, DAI Min.
Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
|